EPi-Sense Guided Coagulation System
AtriCure, Inc. · Decision date Apr 28, 2021
What did the FDA approve?
The FDA database entry for P200002 records an approval decision dated April 28, 2021, for the EPi-Sense Guided Coagulation System from AtriCure, Inc. The stated scope covers treatment of symptomatic long-standing persistent atrial fibrillation, defined as continuous atrial fibrillation lasting more than 12 months, when augmented in a hybrid procedure with an endocardial catheter listed in the instructions for use.
The patient population described in the statement is limited to people who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug, and for whom the expected benefit from rhythm control outweighs the potential known risks associated with a hybrid procedure, such as delayed post-procedure inflammatory pericardial effusions. The entry does not provide clinical outcome data or independent evidence of safety or effectiveness.
FDA approval order statement
Approval for the EPi-Sense Guided Coagulation System is intended for the treatment of symptomatic long-standing persistent atrial fibrillation (continuous atrial fibrillation greater than 12 months duration) when augmented in a hybrid procedure with an endocardial catheter listed in the instructions for use, in patients who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug (AAD); and, in whom the expected benefit from rhythm control outweighs the potential known risks associated with a hybrid procedure such as delayed post-procedure inflammatory pericardial effusions.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 28, 2021
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200002
- Regulatory pathway
- Premarket approval application
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- Decision code
- APPR
- Decision date
- Apr 28, 2021
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Surgical cardiac ablation device, for treatment of atrial fibrillation.
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200002 received
Application receipt date recorded by FDA.
P200002 · FDA decision
APPR
P200002/S015 · Related supplement
EPi- Sense ST Coagulation System
Timeline entries are records held by MedtechLedger for P200002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EPi- Sense ST Coagulation SystemP200002/S015 | AtriCure, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code OCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Synergy Ablation SystemP100046/S021 | AtriCure, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| AtriCure, Inc. | PMA approval | Dec 14, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
AtriCure, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7555 Innovation Way, Mason, OH, 45040
Sources and methodology
- Original FDA record: P200002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

